Immunity to WT1 in the animal model and in patients with acute myeloid leukemia

Blood

Volumn 96, Issue 4, 2000, Pages 1480-1489

  Gaiger, A ^a   Reese, V ^a   Disis, M L ^a   Cheever, M A ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER ANTIBODY; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FEMALE; GENE OVEREXPRESSION; HELPER CELL; HUMAN; HUMAN CELL; IMMUNIZATION; IMMUNOGENICITY; LEUKEMOGENESIS; MOUSE; NEPHROBLASTOMA; NONHUMAN; PRIORITY JOURNAL; TUMOR IMMUNITY;

EID: 0034663331     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v96.4.1480     Document Type: Article

References (54)

1. A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E
2. Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes
3. Definition of tumor antigens suitable for vaccine construction
4. The candidate Wilms' tumour gene is involved in genitourinary development
5. An internal deletion within an 11p13 zinc finger gene contributes to the development of Wilm's tumor
6. Nuclear localization of the protein encoded by the Wilms' tumor gene WT1 in embryonic and adult tissues
7. Expression of the Wilms' tumor gene (Wt 1) in human leukemias
8. Expression of the candidate Wilms' tumor gene, Wt-1, in human leukemia cells
9. WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia
10. High levels of Wilms' tumor gene (wt1) mRNA in acute myeloid leukemias are associated with a worse long-term outcome
11. Detection by monoclonal antibodies of the Wilms' tumor (WT1) nuclear protein in patients with acute leukemia
12. A Prognostic significance of WT1 gene expression at diagnosis in adult de nero acute myeloid leukemia
13. Wilms' tumour gene (wt1) expression at diagnosis has no prognostic relevance in childhood acute lymphoblastic leukaemia treated by an intensive chemotherapy protocol
14. WT1 and GATA1 expression in myelodysplastic syndrome and acute leukemia
15. The Wilms' tumor gene WT1 is a good marker for diagnosis of disease progression of myelodysplastic syndromes
16. Altered expression of the WT1 Wilms tumor suppressor gene in human breast cancer
17. Analysis of the 11p13 Wilms' tumor suppressor gene (WT1) in ovarian tumors
18. Expression of the wt1 Wilms' tumor gene by normal and malignant human melanocytes
19. Detection of WT1 gene expression in patients with solid tumors
20. Molecular staging of testicular cancer using polymerase chain reaction of the testicular cancer-specific genes
21. Expression of the Wilms' tumor gene WT1 in solid tumors and its involvement in tumor cell growth
22. Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus
23. Hypermethylation of the Wilms' tumor suppressor gene CpG island in human breast carcinomas
24. Internal translation initiation generates novel WT1 protein isoforms with distinct biological properties
25. Alternative splicing and genomic structure of the Wilms tumor gene WT1
26. Binding of the Wilms' tumor locus zinc finger protein to the EGR-1 consensus sequence
27. Transcriptional repression mediated by the WT1 Wilms tumor gene product
28. Repression of the insulin-like growth factor gene by the Wilms tumor suppressor WT1
29. Expression of the Wilms' tumor gene (WT1) in normal hemopoiesis
30. A WT1 antisense oligonucleotide inhibits proliferation and induces apoptosis in myeloid leukemia cell lines
31. Growth inhibition of human leukemic cells by WT1 (Wilms tumor gene) antisense oligodeoxynucleotides: Implications for the involvement of WT1 in leukemogenesis
32. Constitutive expression of the Wilms' tumor gene (WT1) in the leukemic cell line U937 blocks parts of the differentiation program
33. Constitutive expression of the Wilms' tumor gene WT1 inhibits the differentiation of myeloid progenitor cells but promotes their proliferation in response to granulocyte-colony stimulating factor (G-CSF)
34. Isolation, characterization and expression of the mufine Wilms' tumor gene (Wt1) during kidney development
35. Expression of the tumor suppressor gene WT1 in both human and mouse bone marrow
36. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side chains
37. Identifying antigenic T cell sites
38. A sequence pattern common to T cell epitopes
39. Structural analysis of peptides capable of binding to more than I antigen
40. Empty MHC class I molecules come out in the cold
41. Existent T cell and antibody immunity to HER-2/neu protein in patients with breast cancer
42. T-cell immunity to the joining region of p210BCR-ABL protein
43. In vitro generation of human cytolytic T ceils specific for peptides derived from HER-2/neu proto-oncogene protein
44. Genetically designed affinity chromatography using a novel metal chelate absorbent
45. Increase of bcr-abl chimeric mRNA expression in tumor cells of patients with chronic myeloid leukemia precedes disease progression
46. Expression of HOXC4, HOXC5, and HOXC6 in human lymphoid cell lines, leukemias, and benign and malignant lymphoid tissue
47. p53 Antibodies in patients with various types of cancer: Assay, identification, and characterization
48. Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer
49. Cancer immunotherapy targeting Wilms' tumor gene WT1 product
50. + hematopoietic progenitors during fetal development and early clonogenic growth
51. Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia
52. + progenitors
53. HLA class I-restricted lysis of leukemia cells by a CD8(+) cytotoxic T-lymphocyte clone specific for WT1 peptide
54. + progenitor cells by cytotoxic T lymphocytes specific for WT1